What You Need to Know About Genetics and Prostate Cancer
What is a ‘cancer gene’? How genetic mutations lead to cancer IPCSG Newsletter A Patient-Friendly Guide for the Informed Prostate Cancer Support Group February 2026 | Informed Prostate Cancer Support Group (IPCSG) BLUF — Bottom Line Up Front • About 12% of all prostate cancers are driven by inherited (germline) gene mutations, most commonly in BRCA2, BRCA1, ATM, CHEK2, and the Lynch syndrome genes. • Men carrying a BRCA2 mutation face a 2–8× higher lifetime risk of prostate cancer, more aggressive disease, and earlier onset than the general population. • NCCN guidelines now recommend genetic counseling and testing for all men with metastatic, high-risk, or very-high-risk prostate cancer, as well as those with a suggestive family history. • Your germline mutation status can directly guide treatment: PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) are FDA-approved specifically for men whose tumors harbor HRR-pathway mutations. • Tumor (somatic) genetic testing an...